Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG , Wang KK, Wu X
Call/Text us at: (801) 318-4260 to Order Your Wellness, Our Priority At TruHealth PT, were not just selling products
It also supports angiogenesis and modulates inflammation
10.1177/0271678X15617954 242 PlancheV.CoupP.HelmerC.Le GoffM.AmievaH.TisonF.et al (2019)
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)